Debriefing ACC 2026: Key Cardiovascular Trials and Their Clinical Implications for Pharmacists

In this episode of The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest, host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, welcomes back Kyle Fischer, PharmD, BCCP, MBA, a cardiology clinical pharmacy specialist at Ascension Medical Center Austin at Dell Medical School in Austin, Texas, to debrief on late-breaking trials from the 2026 American College of Cardiology (ACC) Scientific Sessions. Fischer, a PGY2-trained cardiology pharmacist, shifts roles from previewer to debriefer as the two discuss the clinical significance of key studies and their implications for cardiovascular pharmacotherapy.
Together, Beavers and Fischer review 5 trials from ACC 2026, emphasizing shared decision-making and the evolving landscape of cardiovascular pharmacotherapy throughout their discussion.

• SPIRIT-HF 
• CHAMPION-AF 
• SMART-DECISION 
• VESALIUS-CV (sub-study) 
• CORAL REEF 
• Ez-PAVE